Back to School: How biopharma can reboot drug development. Access exclusive analysis here

LoneStar Heart: Straight to the heart

LoneStar Heart developing trio of technologies for advanced heart failure

Therapies for heart failure are palliative and aimed primarily at delaying pathological cardiac remodeling and progression to advanced disease. LoneStar Heart Inc. is developing a trio of technologies that it believes have the potential to restore the heart's structure and function, reversing disease progression.

President and COO Frank Ahmann said LoneStar's programs target patients with New York Heart Association (NYHA) Class II-III heart failure because "these patients are not optimally treated with pharmaceuticals and are not yet candidates for more

Read the full 792 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers